Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsDik J. Kwekkeboom, Eric P. Krenning, Jaap J.M. Teunissen et al.|Journal of Clinical Oncology|2005Cited by 659
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsDik J. Kwekkeboom, Eric P. Krenning, Ananth Srinivasan et al.|European Journal of Nuclear Medicine and Molecular Imaging|2001Cited by 471
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceRoelf Valkema, Eric P. Krenning, Marion de Jong et al.|Seminars in Nuclear Medicine|2002Cited by 433
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Eric P. Krenning, Roelf Valkema et al.|Seminars in Nuclear Medicine|2002Cited by 347
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.Roelf Valkema, Eric P. Krenning, Stanislas Pauwels et al.|PubMed|2005Cited by 334